Findings from a prospective study have identified 2 potentially useful biomarkers for central nervous system lymphoma (CNSL). Chemokine CXCL13 may be valuable as a prognostic marker, while both CXCL9 and CXCL13 may be useful to monitor therapy.
Identification of promising biomarkers for central nervous system lymphoma
Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.